Navigation Links
Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators
Date:10/6/2010

TORONTO, Oct. 6 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, growth in the $2 billion US cardiac resynchronization therapy defibrillator market will be supported by the expanded approval of Boston Scientific's chronic resynchronization therapy defibrillators in New York Heart Association class I and II patients.

The New York Heart Association classification system ranks heart failure patients according to different levels of severity, with Class I being the least severe and Class IV the most severe. Classes I and II are considered mild forms of heart failure with relatively minor symptoms.  Classes III and IV are considered to be moderate and severe forms of heart failure, and Class IV patients experience discomfort at rest and very little physical activity.

Cardiac resynchronization therapy defibrillator procedures will grow due to results from the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. MADIT-CRT was a randomized trial designed to compare patients in New York Heart Association Class I or II who received a cardiac resynchronization therapy defibrillator with those who received an implantable cardioverter defibrillator; the trial found patients who received a cardiac resynchronization therapy defibrillator had a 34% reduction in the risk of heart failure or death.

"As a result of this trial, in March 2010, an FDA panel of cardiologists voted in favor of expanding the indication of cardiac resynchronization therapy defibrillators to include mild heart failure patients, increasing the potential patient pool," says Julie McLaughlin, Analyst at MRG.  "This decision was upheld in September 2010 when the FDA expanded the indication for Boston Scientific's cardiac resynchronization therapy defibrillator devices to include high risk New York Heart Association Class I and II patients. 
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
2. Enobia Reports Positive Results For Phase II Trial of ENB-0040 in Juvenile Hypophosphatasia
3. Dynatronics Announces Positive Year-end Results
4. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
5. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
6. ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmins Potential to Transform the Treatment of Retinal Disorders
7. Bionovo Receives Positive Guidance from FDA on Menerba®
8. OXIS International, Inc. Announces Publication of Positive Results of Ergothioneine Safety Study in the Journal TOXICOLOGY
9. Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
10. Excaliard Announces Positive Data From Phase 2 Clinical Trial of Its Anti-Scarring Drug, EXC 001
11. Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Takeda Pharmaceuticals International, Inc., a wholly-owned subsidiary ... its Pharmaceutical Development Division has entered into strategic ... and Quintiles, two of the world,s largest full-service ... the agreements, Covance and Quintiles will work in ...
... Viral Genetics, Inc. (Pink Sheets: VRAL ) ... and Advisor Mr. Richard Gerstner will receive the Lauren F. ... award presentation is set for the Illusions of Lyme Gala, ... being recognized for her research on Targeted Peptide treatment for ...
Cached Medicine Technology:Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles 2Viral Genetics' Researcher and Advisor Set to Share Award 2Viral Genetics' Researcher and Advisor Set to Share Award 3
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review recently updated ... what to do to eliminate the root cause of ... review that readers can easily learn what foods to avoid ... Vkool also informs in its Kidney Disease Solution review that ... naturally. The book consists of a collection of natural remedies ...
(Date:7/13/2014)... 2014 Celebrity fitness trainer and former ... promotional partnership with Aqua Health Labs for their flagship ... supplement . The collaboration was recently announced live on ... trainer , actor, model, and a two time World ... celebrities, he has prepared stars including Demi Moore, Hilary ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, the innovative ... http://www.HealthYourself101.com will expand people’s understanding of the causes, consequences, ... out to provide a health education platform on this modern ... say it? – entertaining to dig into and learn from. ... remote learner – the solitary individual signing on from a ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers of ... a new selection of beautiful evening dresses ... promotion for these evening gowns. Now, everybody can enjoy ... thousands of graceful gowns in its online store. Most ... Italy and many other countries. They are highly appreciated ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2
... cause of death in the Intensive Care Unit (ICU) is ... central nervous system// and cardiovascular system. The study also revealed ... who are out of the ICU but still in hospital ... ,This study is published in the journal Critical Care. Investigation ...
... were performed, much has been learned about illegal transplants of ... are quite common in countries like India and China ... Africa, people sell their kidneys to foreigners. ,Much ... news was in Jan 2006, about an Indian who died ...
... feelings either way has been brought up by senior doctors ... mercy killing of// new borns who are severely disabled. ... this recommendation as the solution to the incresing numbers of ... alive because of the advanced technology in the medical ...
... injuries like low back pain and disc disorder now ... gas could bring better results than conventional// surgery. ... started gaining ground in western countries, according to senior ... subject., ,'Ozonucleolysis or ozone discectomy for curing spinal ...
... charged with cheating the organisation he earlier worked for has ... Cell of Delhi Police arrested Alok Tomar, a former editor ... ,Tomar was arrested after he flew into the capital ... Deputy Commissioner of Police Alok Kumar. ,Kumar said ...
... rabies, a farmer's extended family in Bihar has to now ... as they had drunk the milk of the infected cows. ... in Dakhin Tola in Purnea district, were bitten by a ... weeks, according to local media reports here. ,The farmer's ...
Cached Medicine News:Health News:Consider Euthanasia For Severely Disabled Babies, College Tells Doctors 2Health News:Ozone Treatment - A Good Alternative For Spinal Injury 2